This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • Oncology  • Ovarian Cancer  • Surgery  • Surgical Interventions  • Urology  • Women's Health  • Women's Health, Other  • Prognosis/ Outcomes  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 107 words of the full text and any section headings.

To the Editor: The study of women with a BRCA1 or BRCA2 mutation by Ms Finch and colleagues¹ found that for cancer, the adjusted relative risk reduction associated with bilateral salpingo-oophorectomy was 80% (95% confidence interval, 42%-93%). While this is valuable information for advising women at risk, no mention was made of morbidity or mortality secondary to this surgery.

In counseling patients about potential risks vs benefits, these are important outcomes that were not addressed in this study. I would be particularly interested in morbidity and mortality data in the group of women who underwent surgery who were found not to have cancer.

Financial Disclosures: None reported.

Dennis McCunniff, MD
dmc55@msn.com
Department of Gynecology
Medical Park Hospital
Winston-Salem, NC

1. Finch A, Beiner M, Lubinski J, et al. Salpingo-oopherectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296:185-192. FREE FULL TEXT

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;296:2558.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Morbidity or Mortality Outcomes Associated With Prophylactic Salpingo-oophorectomy—Reply
Steven A. Narod and Amy Finch
JAMA. 2006;296(21):2558.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation
Amy Finch, Mario Beiner, Jan Lubinski, Henry T. Lynch, Pal Moller, Barry Rosen, Joan Murphy, Parviz Ghadirian, Eitan Friedman, William D. Foulkes, Charmaine Kim-Sing, Teresa Wagner, Nadine Tung, Fergus Couch, Dominique Stoppa-Lyonnet, Peter Ainsworth, Mary Daly, Barbara Pasini, Ruth Gershoni-Baruch, Charis Eng, Olufunmilayo I. Olopade, Jane McLennan, Beth Karlan, Jeffrey Weitzel, Ping Sun, Steven A. Narod, and for the Hereditary Ovarian Cancer Clinical Study Group
JAMA. 2006;296(2):185-192.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update
Rizzo et al.
JCO 2008;26:132-149.
ABSTRACT | FULL TEXT  

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update
Rizzo et al.
Blood 2008;111:25-41.
ABSTRACT | FULL TEXT  

American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
Lyman et al.
JCO 2007;25:5490-5505.
ABSTRACT | FULL TEXT  

Bleeding and Thrombosis Risks in Plasma Cell Dyscrasias
Eby
ASH Education Book 2007;2007:158-164.
ABSTRACT | FULL TEXT